The FDA gives marketing approval for a test that screens for Duchenne muscular dystrophy in newborns; acetaminophen is facing a possible statewide ban in California; the Supreme Court will not rush its decision on the Affordable Care Act.
The FDA has given marketing approval for the GSP Neonatal Creatine Kinase-MM kit, which tests for Duchenne muscular dystrophy (DMD) in newborns, making it the first such approval for the rare muscle disorder, according to JAMA. Laboratories now have the choice to add this test to their newborn screening panels, as it is not yet required by HHS’ Recommended Uniform Screening Panel for newborn screenings. Results can detect potential muscle injury, but they must be confirmed via muscle biopsy or genetic testing.
Acetaminophen, an integral ingredient in more than 600 prescription and OTC medications, is facing a ban in California, says MSN. Although it is often used to reduce fevers and pain, acetaminophen also is closely connected to phenacetin, which was banned in 1983 because it was shown to cause cancer. Proposition 65 mandates that California has to warn its citizens of cancerous chemicals. Those opposed to reclassifying acetaminophen under this law caution against the weak cancer link, while supporters emphasize product safety. The public comment period closes on January 27.
Democrats were disheartened yesterday when the Supreme Court refused to hand down a final decision on the Affordable Care Act (ACA) before this year’s presidential election, details Politico. The justices claim there is no “emergency,” while Democrats worry about possible harm to those who currently have coverage under the law. Previously, a federal judge in Texas declared the ACA unconstitutional. Republicans, meanwhile, cannot agree on an ACA replacement. Last summer, CMS Administrator Seema Verma’s plan was struck down. The new Supreme Court term begins in October.
"The Barriers Are Real": Antoine Keller, MD, on Geography and Cardiovascular Health
April 18th 2025Health care disparities are often driven by where patients live, explained Antoine Keller, MD, as he discussed the complex, systematic hurdles that influence the health of rural communities.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Empowering Teams Begins With Human Connection: Missy Hopson, PhD
April 16th 2025Missy Hopson, PhD, Ochsner Health, discussed in detail the challenges of strengthening the patient-centered workforce, the power of community reputation for encouraging health care careers, and the influence of empowered workforces on patient outcomes.
Read More